1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Digital Technologies as Tools to Screen and Monitor Alzheimer's Disease (AD) and Related Dementias (ADRD) (NIA Contract Topic NIH/NIA 011) is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). This contract topic encourages the development and demonstration of digital technologies to screen and monitor Alzheimer's Disease (AD) and Related Dementias (ADRD).
The goal is to develop qualified medical device development tools used to assess medical devices subject to FDA regulation. NIA is interested in AI/ML methods for early detection and monitoring of AD/ADRD.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute on Aging (NIA), National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses eligible for NIH SBIR grant funding. Confirm the full requirements in the official notice before applying.
The current listing shows phase I: $500,000 for 12 months; Phase II: $2.5 million for 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Digital Technologies as Tools to Screen and Monitor Alzheimer's Disease (AD) and Related Dementias (ADRD) (NIA Contract Topic NIH/NIA 011) is funded by National Institute on Aging (NIA), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). This program supports small molecule drug discovery and development for disorders of the nervous system, including Alzheimer's disease and related dementias.
Small Business Technology Transfer (STTR) Program is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA STTR program encourages small businesses to collaborate formally with research institutions to develop and commercialize innovative treatments or technologies to help people enjoy healthier lives as they age, including solutions for Alzheimer's disease and related dementias. This program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.
NIA Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA Small Business Programs offer non-dilutive funding to small businesses for research and development (R&D) of innovations that address healthy aging, Alzheimer's disease (AD), and AD-related dementias (ADRD). This includes technologies and interventions to prevent, diagnose, treat, monitor, or slow progression of AD/ADRD, cognitive decline, age-related sleep disorders, and delirium, as well as assistive devices, robotics, sensors, and digital health products to enhance care and reduce caregiver burden.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
NIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read articleNew NIH awards have fallen 34% in 2026, NSF is running months behind, and a proposed OMB rule would let political appointees terminate grants mid-stream. The funding environment for academic research has structurally changed. Here is a clear-eyed diversification strategy for PIs, research offices, and institutions that cannot wait for the political fight to resolve.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read article